A randomized, double-blind, placebo-controlled study to assess the safety and tolerability of PN-1094A after single and multiple ascending doses of PN-10943A in normal healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs PN 10943A (Primary)
- Indications Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Protagonist Therapeutics
- 06 Nov 2019 According to a Protagonist Therapeutics media release, results were presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting.
- 01 Aug 2019 According to a Protagonist Therapeutics media release, complete data from the trial will be presented at the American College of Gastroenterology Conference in October 2019.
- 01 Aug 2019 Results presented in the Protagonist Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History